Literature DB >> 22290130

Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty?

Amy Sewick1, Amun Makani, Chia Wu, Judith O'Donnell, Keith D Baldwin, Gwo-Chin Lee.   

Abstract

INTRODUCTION: It is unclear which antibiotic regimen provides the best prophylaxis against surgical site infection (SSI) in patients undergoing hip and knee surgery. QUESTIONS/PURPOSES: Therefore, we determined whether dual antibiotic prophylaxis (1) reduced the rate of SSI compared to single antibiotic prophylaxis and (2) altered the microbiology of SSI.
METHODS: We retrospectively reviewed 1828 primary THAs and TKAs performed between September 1, 2008 and December 31, 2010. We divided patients into two groups: (1) those who received a dual prophylactic antibiotic regimen of cefazolin and vancomycin (unless allergy), or (2) received cefazolin (unless allergy) as the sole prophylactic antibiotic. There were 701 males and 1127 females with an average age of 56 years (range, 15–97 years). We limited followup to 1 year, presuming subsequent infections were not related to the initial surgery.
RESULTS: During this period, there were 22 SSIs (1.2%). The infection rates for dual antibiotic prophylaxis compared to a single antibiotic regimen were 1.1% and 1.4%, respectively. Of 1328 patients treated with dual antibiotic prophylaxis, only one (0.08%) SSI was culture positive for methicillin resistant Staphylococcus aureus (MRSA), while four of 500 patients (0.8%) receiving only cefazolin prophylaxis had culture positive MRSA infection at the time of reoperation.
CONCLUSION: The addition of vancomycin as a prophylactic antibiotic agent apparently did not reduce the rate of SSI compared to cefazolin alone. Use of vancomycin in addition to cefazolin appeared to reduce the incidence of MRSA infections; however, the number needed to treat to prevent a single MRSA infection was very high. LEVEL OF EVIDENCE: Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2012        PMID: 22290130      PMCID: PMC3441989          DOI: 10.1007/s11999-012-2255-1

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  39 in total

1.  Institutional prescreening for detection and eradication of methicillin-resistant Staphylococcus aureus in patients undergoing elective orthopaedic surgery.

Authors:  David H Kim; Maureen Spencer; Susan M Davidson; Ling Li; Jeremy D Shaw; Diane Gulczynski; David J Hunter; Juli F Martha; Gerald B Miley; Stephen J Parazin; Pamela Dejoie; John C Richmond
Journal:  J Bone Joint Surg Am       Date:  2010-07-07       Impact factor: 5.284

2.  New opportunities for reducing risk of surgical site infection. Roundtable discussion.

Authors:  Mark A Malangoni; William G Cheadle; Thomas F Dodson; Pascal M C E Dohmen; David Jones; Kushagra Katariya; Shyam Kolvekar; Joshua A Urban
Journal:  Surg Infect (Larchmt)       Date:  2006       Impact factor: 2.150

Review 3.  Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement.

Authors:  William A Jiranek; Arlen D Hanssen; A Seth Greenwald
Journal:  J Bone Joint Surg Am       Date:  2006-11       Impact factor: 5.284

4.  The epidemiology of revision total hip arthroplasty in the United States.

Authors:  Kevin J Bozic; Steven M Kurtz; Edmund Lau; Kevin Ong; Thomas P Vail; Daniel J Berry
Journal:  J Bone Joint Surg Am       Date:  2009-01       Impact factor: 5.284

Review 5.  Prophylactic antibiotics in orthopaedic surgery.

Authors:  Laura Prokuski
Journal:  J Am Acad Orthop Surg       Date:  2008-05       Impact factor: 3.020

6.  Antibiotic prophylaxis in primary hip and knee arthroplasty: comparison between cefuroxime and two specific antistaphylococcal agents.

Authors:  Minos E Tyllianakis; Athanasios Ch Karageorgos; Markos N Marangos; Alkis G Saridis; Elias E Lambiris
Journal:  J Arthroplasty       Date:  2010-04-08       Impact factor: 4.757

7.  Comparison of routine prophylaxis with vancomycin or cefazolin for femoral neck fracture surgery: microbiological and clinical outcomes.

Authors:  Jacques Merrer; Laetitia Desbouchages; Valérie Serazin; Jimmy Razafimamonjy; François Pauthier; Michel Leneveu
Journal:  Infect Control Hosp Epidemiol       Date:  2006-11-21       Impact factor: 3.254

8.  Measurement of foot traffic in the operating room: implications for infection control.

Authors:  Raymond J Lynch; Michael J Englesbe; Lisa Sturm; Amira Bitar; Karn Budhiraj; Sandeep Kolla; Yuliya Polyachenko; Mary G Duck; Darrell A Campbell
Journal:  Am J Med Qual       Date:  2009 Jan-Feb       Impact factor: 1.852

Review 9.  Prophylactic antibiotics in hip and knee arthroplasty.

Authors:  John Meehan; Amir A Jamali; Hien Nguyen
Journal:  J Bone Joint Surg Am       Date:  2009-10       Impact factor: 5.284

10.  The epidemiology of revision total knee arthroplasty in the United States.

Authors:  Kevin J Bozic; Steven M Kurtz; Edmund Lau; Kevin Ong; Vanessa Chiu; Thomas P Vail; Harry E Rubash; Daniel J Berry
Journal:  Clin Orthop Relat Res       Date:  2009-06-25       Impact factor: 4.176

View more
  25 in total

1.  CORR Insights(®): Is Vancomycin-only Prophylaxis for Patients With Penicillin Allergy Associated With Increased Risk of Infection After Arthroplasty?

Authors:  Gwo-Chin Lee
Journal:  Clin Orthop Relat Res       Date:  2016-01-27       Impact factor: 4.176

2.  Vancomycin Prophylaxis for Total Joint Arthroplasty: Incorrectly Dosed and Has a Higher Rate of Periprosthetic Infection Than Cefazolin.

Authors:  Michael M Kheir; Timothy L Tan; Ibrahim Azboy; Dean D Tan; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2017-07       Impact factor: 4.176

3.  Editor's Spotlight/Take 5: Addition of Vancomycin to Cefazolin Prophylaxis Is Associated With Acute Kidney Injury After Primary Joint Arthroplasty.

Authors:  M Daniel Wongworawat
Journal:  Clin Orthop Relat Res       Date:  2015-04-25       Impact factor: 4.176

4.  CORR Insights(®): Addition of Vancomycin to Cefazolin Prophylaxis Is Associated with Acute Kidney Injury After Primary Joint Arthroplasty.

Authors:  Han-Xiao Zhu; Xun-Zi Cai
Journal:  Clin Orthop Relat Res       Date:  2015-01-06       Impact factor: 4.176

5.  Prevention of surgical site infections in bone and joint procedures.

Authors:  Ralf-Peter Vonberg; Petra Gastmeier
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

6.  Targeted use of vancomycin as perioperative prophylaxis reduces periprosthetic joint infection in revision TKA.

Authors:  Catherine Liu; Anthony Kakis; Amy Nichols; Michael D Ries; Thomas P Vail; Kevin J Bozic
Journal:  Clin Orthop Relat Res       Date:  2014-01       Impact factor: 4.176

7.  Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplasty.

Authors:  Eduard Tornero; Sebastian García-Ramiro; Juan C Martínez-Pastor; Guillem Bori; Jordi Bosch; Laura Morata; Marta Sala; Misericordia Basora; Josep Mensa; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

8.  Antibacterial activity of joint fluid in cemented total-knee arthroplasty: an in vivo comparative study of polymethylmethacrylate with and without antibiotic loading.

Authors:  Steve W N Ueng; Pang-Hsin Hsieh; Hsin-Nung Shih; Yi-Shan Chan; Mel S Lee; Yuhan Chang
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

9.  Is Vancomycin-only Prophylaxis for Patients With Penicillin Allergy Associated With Increased Risk of Infection After Arthroplasty?

Authors:  Timothy L Tan; Bryan D Springer; John A Ruder; Michael R Ruffolo; Antonia F Chen
Journal:  Clin Orthop Relat Res       Date:  2016-07       Impact factor: 4.176

10.  Addition of Vancomycin to Cefazolin Prophylaxis Is Associated With Acute Kidney Injury After Primary Joint Arthroplasty.

Authors:  P Maxwell Courtney; Christopher M Melnic; Zachary Zimmer; Jason Anari; Gwo-Chin Lee
Journal:  Clin Orthop Relat Res       Date:  2015-07       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.